Comprehensive evaluation of the cancer-immunity cycle demonstrated enhanced immune activation in tumors with reduced FAM174B expression, evidenced by elevated scores in critical immune processes such as lymphocyte recruitment and tumor cell elimination. Here, FAM174B is linked to neoplasm.